Polymyositis Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Argenx, Immunoforge Co. Ltd., Chester Oddis, Kezar Life Sciences, Inc., Mallinckrodt, Merck KGaA, Astellas

The Key Polymyositis Companies in the market include - Argenx, Immunoforge Co. Ltd., Chester Oddis, Kezar Life Sciences, Inc., Mallinckrodt, Merck KGaA, Astellas Pharma Inc, Genentech, Pfizer, Bristol-Myers Squibb, and others.

DelveInsight's "Polymyositis Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Polymyositis, historical and forecasted epidemiology as well as the Polymyositis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Polymyositis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Polymyositis Market Forecast [https://www.delveinsight.com/sample-request/polymyositis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Polymyositis Market Report:

*
The Polymyositis market size was valued approximately ~USD 114 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

*
In 2023, Germany had the largest Polymyositis market size among EU countries, valued at approximately USD 6 million, while Spain recorded the smallest market size at around USD 2 million.

*
The anticipated introduction of new therapies, including Anifrolumab (SAPHNELO), PF-06823859, and Enpatoran (M5049), among others, is expected to drive changes in the total market size of Polymyositis in the coming years.

*
In 2023, the United States had the largest market size for Polymyositis among the 7MM, reaching approximately USD 86 million. This figure is anticipated to grow at a compound annual growth rate (CAGR) of 15.8% throughout the forecast period.

*
According to DelveInsight's analysis, the estimated total number of diagnosed prevalent cases of Polymyositis in the 7MM was approximately 80,000 in 2023.

*
In 2023, Germany had the highest number of diagnosed prevalent cases of Polymyositis among European countries, with around 9,000 cases, followed by France with approximately 7,000 cases. In contrast, Spain had the lowest prevalent population, with about 3,000 cases.

*
In 2023, Japan reported around 12,000 diagnosed prevalent cases of Polymyositis, representing roughly 16% of the total cases across the 7MM.

*
According to DelveInsight's analysis, females in Japan were more commonly affected by Polymyositis than males, with around 9,000 female cases compared to 3,000 male cases in 2023.

*
Key Polymyositis Companies: Argenx, Immunoforge Co. Ltd., Chester Oddis, Kezar Life Sciences, Inc., Mallinckrodt, Merck KGaA, Astellas Pharma Inc, Genentech, Pfizer, Bristol-Myers Squibb, and others

*
Key Polymyositis Therapies: Efgartigimod, PF1801, tocilizumab, KZR-616, Adrenocorticotropic Hormone Gel, M5049 high dose, Tacrolimus, Rituximab, Froniglutide, PF-06823859, Abatacept subcutaneous, and others

*
The Polymyositis epidemiology based on gender analyzed that Polymyositis affects females more as compared to males

*
The Polymyositis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Polymyositis pipeline products will significantly revolutionize the Polymyositis market dynamics.

Polymyositis Overview

Polymyositis is a rare, chronic inflammatory muscle disease characterized by muscle weakness and inflammation. It belongs to a group of diseases called inflammatory myopathies and primarily affects the skeletal muscles, which are responsible for movement.

Get a Free sample for the Polymyositis Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/polymyositis-market [https://www.delveinsight.com/report-store/polymyositis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Polymyositis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Polymyositis Epidemiology Segmentation:

The Polymyositis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Polymyositis

*
Prevalent Cases of Polymyositis by severity

*
Gender-specific Prevalence of Polymyositis

*
Diagnosed Cases of Episodic and Chronic Polymyositis

Download the report to understand which factors are driving Polymyositis epidemiology trends @ Polymyositis Epidemiology Forecast [https://www.delveinsight.com/sample-request/polymyositis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Polymyositis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Polymyositis market or expected to get launched during the study period. The analysis covers Polymyositis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Polymyositis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Polymyositis Therapies and Key Companies

*
Efgartigimod: Argenx

*
PF1801: Immunoforge Co. Ltd.

*
tocilizumab: Chester Oddis

*
KZR-616: Kezar Life Sciences, Inc.

*
Adrenocorticotropic Hormone Gel: Mallinckrodt

*
M5049 high dose: Merck KGaA

*
Tacrolimus: Astellas Pharma Inc

*
Rituximab: Genentech

*
Froniglutide: Immunoforge Co. Ltd.

*
PF-06823859: Pfizer

*
Abatacept subcutaneous: Bristol-Myers Squibb

Discover more about therapies set to grab major Polymyositis market share @ Polymyositis Treatment Landscape [https://www.delveinsight.com/sample-request/polymyositis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Scope of the Polymyositis Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Polymyositis Companies: Argenx, Immunoforge Co. Ltd., Chester Oddis, Kezar Life Sciences, Inc., Mallinckrodt, Merck KGaA, Astellas Pharma Inc, Genentech, Pfizer, Bristol-Myers Squibb, and others

*
Key Polymyositis Therapies: Efgartigimod, PF1801, tocilizumab, KZR-616, Adrenocorticotropic Hormone Gel, M5049 high dose, Tacrolimus, Rituximab, Froniglutide, PF-06823859, Abatacept subcutaneous, and others

*
Polymyositis Therapeutic Assessment: Polymyositis current marketed and Polymyositis emerging therapies

*
Polymyositis Market Dynamics: Polymyositis market drivers and Polymyositis market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Polymyositis Unmet Needs, KOL's views, Analyst's views, Polymyositis Market Access and Reimbursement

To know more about Polymyositis companies working in the treatment market, visit @ Polymyositis Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/polymyositis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Polymyositis Market Report Introduction

2. Executive Summary for Polymyositis

3. SWOT analysis of Polymyositis

4. Polymyositis Patient Share (%) Overview at a Glance

5. Polymyositis Market Overview at a Glance

6. Polymyositis Disease Background and Overview

7. Polymyositis Epidemiology and Patient Population

8. Country-Specific Patient Population of Polymyositis

9. Polymyositis Current Treatment and Medical Practices

10. Polymyositis Unmet Needs

11. Polymyositis Emerging Therapies

12. Polymyositis Market Outlook

13. Country-Wise Polymyositis Market Analysis (2020-2034)

14. Polymyositis Market Access and Reimbursement of Therapies

15. Polymyositis Market Drivers

16. Polymyositis Market Barriers

17. Polymyositis Appendix

18. Polymyositis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=polymyositis-market-forecasted-to-surge-in-coming-years-20242034-analysis-by-delveinsight-argenx-immunoforge-co-ltd-chester-oddis-kezar-life-sciences-inc-mallinckrodt-merck-kgaa-astellas]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.